Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PATIENT LABELING FOR PROSCAR, FOSAMAX "COME CLOSEST TO SATISFYING" CONSUMER NEEDS IN FILLING CONSUMER ADS "BRIEF SUMMARY" REQUIREMENT -- AARP

Executive Summary

Patient labeling for Merck's prostate therapy Proscar and its osteoporosis treatment Fosamax "come closest to satisfying" consumer needs, the American Association of Retired Persons says in response to FDA's call for comments on its intent to consider agency-approved patient labeling as adequate to fulfill the "brief summary" requirement in direct-to-consumer advertising.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028803

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel